Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT00015912 Terminated - Clinical trials for Recurrent Grade 2 Follicular Lymphoma

Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Start date: July 2001
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of combining thalidomide with interferon alfa in treating patients who have relapsed or refractory non-Hodgkin's lymphoma. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Interferon alfa may interfere with the growth of cancer cells. Combining thalidomide with interferon alfa may kill more tumor cells

NCT ID: NCT00014651 Terminated - Pancreatic Cancer Clinical Trials

Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection

Start date: March 2001
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs such as vapreotide may prevent complications following pancreatic resection. It is not yet known if vapreotide is more effective than no further therapy in preventing side effects of pancreatic resection. PURPOSE: This randomized phase III trial is studying vapreotide to see how well it works compared to a placebo in preventing complications in patients undergoing surgery for pancreatic cancer.

NCT ID: NCT00014443 Terminated - Clinical trials for Brain and Central Nervous System Tumors

Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma

Start date: August 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of combining topotecan and thalidomide in treating patients who have recurrent or refractory malignant glioma.

NCT ID: NCT00012298 Terminated - Clinical trials for Recurrent Small Lymphocytic Lymphoma

Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Start date: April 2001
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I/II trial to study the effectiveness of combining radiolabeled monoclonal antibody therapy and rituximab with and without filgrastim and interleukin-11 in treating patients who have relapsed or refractory non-Hodgkin's lymphoma. Radiolabeled monoclonal antibodies can locate cancer cells and deliver cancer-killing substances to them without harming normal cells. Biological therapies such as filgrastim and interleukin-11 use different ways to stimulate the immune system and stop cancer cells from growing.

NCT ID: NCT00012194 Terminated - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid Tumors

Start date: March 2001
Phase: Phase 1
Study type: Interventional

Phase I trial to study the effectiveness of combining UCN-01 with cisplatin in treating patients who have advanced solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. UCN-01 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and may help cisplatin kill more cancer cells by making tumor cells more sensitive to the drug.

NCT ID: NCT00010205 Terminated - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Benzoylphenylurea in Treating Patients With Advanced Cancer

Start date: December 2000
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of benzoylphenylurea in treating patients with advanced cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

NCT ID: NCT00009984 Terminated - Clinical trials for Recurrent Small Lymphocytic Lymphoma

Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer

Start date: March 2002
Phase: Phase 2
Study type: Interventional

This randomized phase II trial is studying thalidomide and fludarabine to see how well they work compared to thalidomide alone in treating patients with hematologic cancer that has not responded to previous treatment with fludarabine. Thalidomide may stop the growth of hematologic cancer by stopping blood flow to the cancer. Combining thalidomide with fludarabine may increase the effectiveness of chemotherapy by making cancer cells more sensitive to the drug. It is not yet known whether thalidomide is more effective with or without fludarabine for hematologic cancer.

NCT ID: NCT00009958 Terminated - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer

Start date: November 2000
Phase: Phase 1
Study type: Interventional

Phase I trial to compare the effectiveness of vaccine therapy with or without sargramostim in treating patients who have solid tumors. Vaccines may make the body build an immune response to kill tumor cells. Combining colony-stimulating factors such as sargramostim with vaccines may kill more tumor cells.

NCT ID: NCT00008216 Terminated - Lymphoma Clinical Trials

Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer

Start date: July 1996
Phase: Phase 2
Study type: Observational [Patient Registry]

RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This phase II trial is studying the effectiveness of donor peripheral blood stem cell transplant in treating patients with hematologic cancer.

NCT ID: NCT00006916 Terminated - Clinical trials for Brain and Central Nervous System Tumors

Radiation Therapy Followed by Bleomycin in Treating Adult Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme

Start date: June 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiation therapy followed by bleomycin in treating adult patients who have newly diagnosed supratentorial glioblastoma multiforme.